BeSound Opens NYC Flagship to Rebuild Breast Screening Around Ultrasound

The women-founded company is bringing FDA-approved 3D automated breast ultrasound to Manhattan, pairing a pain-free, radiation-free scan with an AI layer that aims to get smarter with every exam

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- BeSound, a next-generation breast imaging platform modernizing cancer screening with FDA-approved 3D ultrasound, today opened its NYC flagship location in Flatiron as it lays the groundwork to scale nationally. Women can book online in minutes with no referral, get same-day appointments, and receive results within 24 to 48 hours for this pain-free scan without compression, radiation, or contrast dye.

BeSound's FDA-approved 3D automated breast ultrasound (ABUS) is designed for dense breast tissue, where up to 40% of cancers can be missed by mammography. Unlike handheld ultrasound, which depends on the skill of the person holding the probe, every BeSound scan captures a standardized, full-volume 3D image of the entire breast. That consistency is the foundation for what BeSound is building next: an AI layer trained on a growing library of structured breast imaging data, designed to help physicians read scans faster, surface findings earlier, and track how a woman's breast tissue changes over time.

"Every BeSound scan captures a complete, standardized 3D image of the breast, and that consistency is what makes AI genuinely useful in breast imaging," said Bailey Renger, Founder and CEO of BeSound. "We're building the foundational AI layer that helps physicians read faster, spot subtle changes earlier, and follow a woman's breast health over time instead of judging a single snapshot. AI doesn't replace the physician. It can give them a sharper view, and it can give women answers sooner."

BeSound's scans are performed via Invenia™ ABUS, manufactured by GE HealthCare, one of the world's largest medical imaging companies. Invenia ABUS was the first FDA-approved supplemental ultrasound screening technology designed specifically to detect cancer in dense breast tissue. Used alongside mammography, ABUS has been clinically proven to detect 55% more invasive cancers than mammograms alone. By pairing GE HealthCare's hospital-grade technology with a model built around the patient experience, BeSound is bringing an exam once found mainly in select hospitals and breast centers to women where they live, with a clear path to scale.

Early detection remains one of the most powerful tools women have against breast cancer. When it's found at a localized stage, before it has spread beyond the breast, the five-year relative survival rate is over 99%. Those odds drop sharply once cancer reaches the lymph nodes or beyond, which is why a cancer hidden by dense tissue carries such a high cost. Yet standard screening guidelines routinely exclude younger women, leaving millions without accessible pathways to early evaluation and proactive care. BeSound is built to move breast care from reactive to proactive: helping women understand their personal risk, supply critical imaging for women with dense breasts, and catch cancer at the stage when it is most treatable.

By the end of 2026, BeSound anticipates offering insurance-covered scans through multiple payers in New York and additional expanding markets, alongside a mobile van to bring screening to more communities and through employer partnerships. To learn more or book an appointment, visit Book Appointment and follow BeSound at @besoundbreast on Instagram.

DISCLAIMER
BeSound supports current breast cancer screening guidelines and does not recommend replacing mammography for eligible women. Women who are eligible for and willing to receive a mammogram should continue to do so. Every woman should consult her healthcare provider to determine what's best for her breast health journey. All clinical services accessible via the BeSound platform are provided exclusively by independent partner medical groups. BeSound is not a healthcare provider.

ABOUT BESOUND
BeSound is transforming how women screen for breast cancer. The platform delivers a welcoming, high-tech screening experience, offering results and guidance from board-certified radiologists within 24 to 48 hours. Founded by former NASA quantum physicist Bailey Renger, BeSound serves the millions of women left behind by traditional mammography, which struggles to detect cancers in dense breast tissue. Powered by FDA-approved 3D automated ultrasound technology and advanced AI research, BeSound is changing the face of early breast cancer detection. Learn more and book an appointment at besoundbreast.com.

PRESS CONTACT
[email protected] 

SOURCE BeSound